MIP and neoplasm: To further confirm the role of type-I IFN in anti-tumor response of MIP immunotherapy in B16F10 melanoma model, we used IFNR1-/- mice in which type-1 IFN receptor has been removed genetically and hence the type-1 IFN signaling is impaired.